Researchclopedia

Research Researchers Institutions Topics Submit About

Command Palette

Search for a command to run...

Researchclopedia

Research Researchers Institutions About

© 2026 Researchclopedia. Powered by OpenAlex under CC0 license.

Margaret von Mehren | Researchclopedia

Back to researchers

Margaret von Mehren

Temple University Health System ORCID

460

Works

33,994

Citations

76

h-index

215

i10-index

Research Topics

Gastrointestinal Tumor Research and Treatment Sarcoma Diagnosis and Treatment Gastric Cancer Management and Outcomes

Affiliations

University of Siena2017–2017

Human Genome Sciences (United States)2007–2007

Northwestern University2009–2009

Brigham and Women's Hospital2011–2011

Novartis (Switzerland)2004–2023

Top Works

Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors

George D. Demetri,Margaret von Mehren,et al.

20024,372 citations

Gastrointestinal disorders and treatments

Neurofibromatosis and Schwannoma Cases

Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor

Michael C. Heinrich,Christopher L. Corless,et al.

20032,288 citations

Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial

George D. Demetri,Peter Reichardt,et al.

20121,393 citations

Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial

Ronald P. DeMatteo,Karla V. Ballman,et al.

20091,352 citations

NCCN Task Force Report: Update on the Management of Patients with Gastrointestinal Stromal Tumors

George D. Demetri,Margaret von Mehren,et al.

20101,217 citations

Soft Tissue Sarcoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology

Margaret von Mehren,John M. Kane,et al.

20221,122 citations

Phase III Randomized, Intergroup Trial Assessing Imatinib Mesylate At Two Dose Levels in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing the Kit Receptor Tyrosine Kinase: S0033

Charles D. Blanke,Cathryn Rankin,et al.

20081,073 citations

Long-Term Results From a Randomized Phase II Trial of Standard- Versus Higher-Dose Imatinib Mesylate for Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing <i>KIT</i>

Charles D. Blanke,George D. Demetri,et al.

20081,001 citations

Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial

George D. Demetri,Margaret von Mehren,et al.

2015817 citations